However, a high incidence of resistance to VEGF signaling-targeted drugs, characterized by disease progression after initial therapy response, has limited the therapeutic success of antiangiogenic drugs in cancer treatment [5,6,7]. The gene discussed is VEGFA; the disease is cancer.